A key part of the Health and Human Services Department’s importation plan for lowering prescription drug prices relies on manufacturers to voluntarily introduce a lower list-priced version of an already marketed brand in the US under a new national drug code.
The approach is the second of two potential “pathways” in a
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?